A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein
Open Access
- 15 January 2017
- journal article
- research article
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 6 (1) , 1-7
- https://doi.org/10.1038/emi.2017.18
Abstract
Emerging Microbes & Infections (2017) 6, e60; doi:10.1038/emi.2017.50; published online 28 June 2017Keywords
This publication has 49 references indexed in Scilit:
- Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunitsNature Communications, 2016
- Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus ChallengeEBioMedicine, 2015
- Receptor-binding domain-based subunit vaccines against MERS-CoVVirus Research, 2015
- A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and VaccinesPLOS ONE, 2013
- Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome CoronavirusJournal of Virology, 2013
- Middle East Respiratory Syndrome Coronavirus Infections in Health Care WorkersNew England Journal of Medicine, 2013
- Hospital Outbreak of Middle East Respiratory Syndrome CoronavirusNew England Journal of Medicine, 2013
- Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013Eurosurveillance, 2013
- A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMCJournal of Infection, 2012
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaNew England Journal of Medicine, 2012